✨ Medicines Approval Notices




30 JUNE NEW ZEALAND GAZETTE 2161

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Zinc (as Zinc Sulphate heptahydrate) 1.0 mg, Copper (as Cupric Sulphate pentahydrate) 0.4 mg, Manganese (as Manganese Sulphate monohydrate) 0.1 mg, Chromium (as Chromic Chloride hexahydrate) 4 mcg, Selenium (as Selenious acid) 20 mcg, Iodide (as Sodium Iodide) 25 mcg, Molybdenum (as Ammonium molybdate tetrahydrate) 25 mcg per ml in 10 ml Solution for infusion Lyphomed Inc., Melrose Park, Illinois, United States of America MTE-7
Polyethylene glycol 4000 5.91% w/v, anhydrous sodium sulphate 0.57% w/v Powder for reconstitution (oral) Rice Steele & Company Limited, Tallaght, Dublin, Ireland Colocler
Papaveretum 20 mg in 1 ml Solution for injection (ampoule) Astra Pharmaceuticals Pty Limited, North Ryde, New South Wales, Australia Papaveretum Injection
Isoflurane 100% Volatile liquid for inhalation Rhone-Poulenc Chemicals Limited, Avonmouth, Bristol, England Isoflurane Inhalation Anaesthetic
Capcipotriol hydrate 50 mcg per g in 30 gram and 100 gram Cream Leo Laboratories Limited, Dublin, Ireland Daivonex
Monobasic sodium phosphate 16.1%, dibasic sodium phosphate 5.9% in 133 ml Enema C B Fleet & Co Inc., Lynchburg, Virginia, United States of America Fleet Enema
Monobasic sodium phosphate 16.1%, dibasic sodium phosphate 5.9% in 66.6 ml Enema C B Fleet & Co Inc., Lynchburg, Virginia, United States of America Fleet Enema for Children
Teicoplanin 100 mg, 200 mg, 400 mg Freeze dried powder for reconstitution for IV or IM injection Gruppo Lepetit S.p.A., Anagni (Frosinone), Italy Targocid Injection
Nabumetone 500 mg Tablet Beecham Pharmaceuticals, Crawley, Sussex, England Relifex
Interferon gamma-lb 100 mcg in 0.5 ml Solution for injection Genentech Inc., South San Francisco, California, United States of America Imukin

Dated this 27th day of June 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go4868

Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Moclobemide 100 mg, 150 mg, 300 mg Tablets F Hoffmann-La Roche Limited, Basle, Switzerland Aurorix
Itraconazole 100 mg Capsule Janssen Pharmaceutica n.v., Belgium Sporanox
Foscarnet trisodium hexahydrate 24 mg/ml in 250 ml and 500 ml Intravenous solution for infusion Astra Pharmaceuticals Production AB., Sodertalje, Sweden and Netherlands Produktielaboratorium voor Bloedtransfusieapparatuur en Infusievloeistoffen B.V., Emmer-Compascuum, The Netherlands Foscavir
Cefpodoxime proxetil 52.18 mg equivalent to 40 mg/5 ml when reconstituted with water Granules for suspension (oral) Usiphar Production Unit, Compeigne, France Orelox


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1994, No 65


NZLII PDF NZ Gazette 1994, No 65





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
27 June 1994
Medicines, Distribution, Consent, Schedule
  • C. Lovelace, Director-General of Health

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
Medicines, Distribution, Consent, Changes, Schedule